These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24118322)

  • 61. Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation.
    Neuburger S; Massenkeil G; Seibold M; Lutz C; Tamm I; le Coutre P; Graf B; Doerken B; Arnold R
    Transpl Infect Dis; 2008 Jul; 10(4):290-3. PubMed ID: 18194367
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Atypical Clinical Presentation of a Newer Generation Anti-Fungal Drug-Resistant Fusarium Infection After a Modified Multi-Visceral Transplant.
    Kandeel A; Abu-Elmagd K; Spinner M; Khanna A; Hashimoto K; Fujiki M; Parsi M; Bennett A; El-Gazzaz G; Abd-Elaal A
    Ann Transplant; 2015 Sep; 20():512-8. PubMed ID: 26334671
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes.
    Grim SA; Berger K; Teng C; Gupta S; Layden JE; Janda WM; Clark NM
    J Antimicrob Chemother; 2012 Mar; 67(3):707-14. PubMed ID: 22184469
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 65. How different is invasive fusariosis in pediatric patients than in adults? A systematic review.
    Rossato L; Carlesse F; Nobrega de Almeida J; Kontoyiannis DP; Colombo AL
    Curr Opin Infect Dis; 2021 Dec; 34(6):619-626. PubMed ID: 34751181
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
    Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
    De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
    Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
    Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
    Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
    Altmannsberger P; Holler E; Andreesen R; Krause SW
    J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
    [No Abstract]   [Full Text] [Related]  

  • 70. Disseminated fusariosis in a patient with bone marrow aplasia.
    Chagas DF; Diniz LM; Lucas EA; Nogueira PSE
    An Bras Dermatol; 2020; 95(5):609-614. PubMed ID: 32723611
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Invasive Fusariosis in Nonneutropenic Patients, Spain, 2000-2015.
    Pérez-Nadales E; Alastruey-Izquierdo A; Linares-Sicilia MJ; Soto-Debrán JC; Abdala E; García-Rodríguez J; Montejo M; Muñoz P; Lletí MS; Rezusta A; de Pipaón MRP; Yáñez L; Merino E; Campos-Herrero MI; Costa-Mateo JM; Fortún J; García-Lozano T; Garcia-Vidal C; Fernández-Ruiz M; Sánchez-Reus F; Castro-Méndez C; Guerrero-Lozano I; Soler-Palacín P; Aguado JM; Martínez-Martínez L; Torre-Cisneros J; Nucci M;
    Emerg Infect Dis; 2021 Jan; 27(1):26-35. PubMed ID: 33352085
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fusarium infection: report of 26 cases and review of 97 cases from the literature.
    Muhammed M; Anagnostou T; Desalermos A; Kourkoumpetis TK; Carneiro HA; Glavis-Bloom J; Coleman JJ; Mylonakis E
    Medicine (Baltimore); 2013 Nov; 92(6):305-316. PubMed ID: 24145697
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fusariosis in cancer patients: 13 case series report and literature review.
    Cuervo-Maldonado SI; Álvarez-Rodríguez JC; Cubides CL; Barrera JC; Montañez-Abril JD; Vergara-Vela EP; Saavedra-Trujillo CH; López-Mora MJ; Mora-Figueroa GE; Celis-Ramírez A; Jaramillo-Calle RM; Parra-Medina R
    Biomedica; 2023 Aug; 43(Sp. 1):41-56. PubMed ID: 37721903
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Voriconazole topical cream formulation: evidence for stability and antifungal activity.
    Bouchand C; Nguyen D; Secretan PH; Vidal F; Guery R; Auvity S; Cohen JF; Lanternier F; Lortholary O; Cisternino S; Schlatter J
    Int J Antimicrob Agents; 2020 Sep; 56(3):106083. PubMed ID: 32659465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.
    Stempel JM; Hammond SP; Sutton DA; Weiser LM; Marty FM
    Open Forum Infect Dis; 2015 Sep; 2(3):ofv099. PubMed ID: 26258156
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in China.
    Zhou Y; Qin Y; Lu Y; Yuan J; Nie J; Liu M; Tian Q; Lan K; Zhou G; Qin Y; He K; Yu J; Jiang Z; Liu J; Liu S; Harypursat V; Chen Y
    Infect Dis Ther; 2022 Aug; 11(4):1575-1590. PubMed ID: 35689792
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical characteristics and outcomes of invasive and non-invasive fusariosis in South Korea.
    Park H; Bae S; Kim MJ; Chong YP; Kim SH; Choi SH; Lee SO; Kim YS; Jung J
    Mycoses; 2023 Mar; 66(3):211-218. PubMed ID: 36349480
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes.
    Matsuo T; Wurster S; Jiang Y; Sasaki K; Tarrand J; Lewis RE; Kontoyiannis DP
    J Antimicrob Chemother; 2024 Feb; 79(2):297-306. PubMed ID: 38073151
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France.
    Demonchy J; Biard L; Clere-Jehl R; Wallet F; Mokart D; Moreau AS; Argaud L; Verlhac C; Pène F; Lautrette A; Bige N; de Jong A; Canet E; Quenot JP; Issa N; Zerbib Y; Bouard I; Picard M; Zafrani L
    Emerg Infect Dis; 2024 Feb; 30(2):215-24. PubMed ID: 38270146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Invasive fusariosis presenting as multiple cutaneous nodules on the trunk and extremities.
    Sunagawa K; Fukumoto T; Hamada T
    J Dermatol; 2022 Feb; 49(2):e69-e70. PubMed ID: 34786752
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.